.An investigational monoclonal antibody may inhibit cell-to-cell transmission of alpha-synuclein and modify disease progression in PD. Alpha-synuclein is a protein found in neurons and other cells that is a major component of pathology that characterizes several neurodegenerative disorders, including PD.
.In a phase 1b double-blind, placebo-controlled, multiple-ascending dose study, 80 patients with PD were randomized into 6 escalating dose cohorts to receive the drug PRX002 or placebo. The patients received 3 monthly doses by IV infusion once every 28 days of the humanized IgG1 monoclonal antibody or placebo for 6 months, and were observed for 3 months.
.The drug was well tolerated and showed a rapid dose- and time-dependent reduction of alpha-synuclein levels of up to 97% after a single dose. This result was consistent after 2 additional monthly doses. No serious or severe treatment-emergent adverse events were reported. No dose-limiting toxicities were observed.